Back to Treatments

Treatment

Osimertinib

1
Conditions
300
Trials
30K
Participants
32%
Average Safety

Condition Evidence

Tracheal, bronchus, and lung cancer

300 trials · 30K participants

90% effectiveness · 32% safety
Osimertinib | DFDA